Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36737314)
Watch
English
New combination therapies with cell-cycle agents
scientific article published on June 2008
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
New combination therapies with cell-cycle agents
(English)
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
author
Gagan Deep
series ordinal
1
object named as
Gagan Deep
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
Rajesh Agarwal
series ordinal
2
object named as
Rajesh Agarwal
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
publication date
1 June 2008
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
published in
Current Opinion in Investigational Drugs
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
volume
9
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
issue
6
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
page(s)
591-604
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
cites work
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Regulation of DNA repair throughout the cell cycle
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
CDK inhibitors in cancer therapy: what is next?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
What's new on CDC25 phosphatase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Targeting checkpoint kinase 1 in cancer therapeutics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Roles of Aurora kinases in mitosis and tumorigenesis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Therapeutic opportunities to control tumor cell cycles
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Prostate cancer chemoprevention by silibinin: bench to bedside
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Cyclin-dependent kinase pathways as targets for cancer treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Targeting the cell cycle: a new approach to cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Cyclins and CDKS in development and cancer: lessons from genetically modified mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Review of UCN-01 development: a lesson in the importance of clinical pharmacology
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Cdc25 phosphatases and cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
The use of CDK inhibitors in oncology: a pharmaceutical perspective
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
G2 checkpoint abrogators as anticancer drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Prostate cancer prevention by silibinin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Chk1 and Chk2 kinases in checkpoint control and cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Complexities in the development of cyclin-dependent kinase inhibitor drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Estimating the world cancer burden: Globocan 2000.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
The DNA damage response: putting checkpoints in perspective
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Cell cycle molecular targets in novel anticancer drug discovery
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
The Hallmarks of Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
29 September 2017
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
28 June 2018
Landmark perspective: Nitrogen mustard therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
28 June 2018
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Effect of silibinin on the growth and progression of primary lung tumors in mice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Targeting polo-like kinase 1 for cancer therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Silibinin efficacy against human hepatocellular carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Regulation of CHK2 by DNA-dependent protein kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
5 September 2018
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440501
retrieved
20 October 2018
Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18516759
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18516759
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18516759
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18516759
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
PMCID
2440501
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
PubMed ID
18516759
1 reference
stated in
Europe PubMed Central
PMCID
2440501
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516759%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit